Form 8-K

8-K — PULSE BIOSCIENCES, INC.

Accession: 0001437749-26-035265

Filed: 2026-11-05

Period: 2026-11-05

CIK: 0001625101

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — plse20261007_8k.htm (Primary)

EX-99.1 — PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED NOVEMBER 5, 2026 - BUSINESS UPDATES AND FINANCIAL RESULTS (ex_1023443.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: plse20261007_8k.htm · Sequence: 1

plse20261007_8k.htm

false

0001625101

2026-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 5, 2026

Pulse Biosciences, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

001-37744

46-5696597

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

3957 Point Eden Way

Hayward, California 94545

(Address of Principal Executive Offices) (Zip Code)

510-906-4600

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common stock, $0.001 par value per share

PLSE

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On November 5, 2026, Pulse Biosciences, Inc. (the “Company”) announced certain financial and operational results for the fiscal quarter ended September 30, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Description

99.1

Press Release issued by Pulse Biosciences, Inc., dated November 5, 2026 - Business Updates and Third Quarter 2026 Financial Results.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PULSE BIOSCIENCES, INC.

Date: November 5, 2026

By:

/s/ Jon Skinner

Jon Skinner

Chief Financial Officer

(Principal Financial Officer)

EX-99.1 — PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED NOVEMBER 5, 2026 - BUSINESS UPDATES AND FINANCIAL RESULTS

EX-99.1

Filename: ex_1023443.htm · Sequence: 2

ex_1023443.htm

Exhibit 99.1

Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results

Completed enrollment of NANOPULSE-AF US IDE pivotal study for treatment of AF with nPulse Cardiac Catheter System

Ended the quarter with $189 million of cash, cash equivalents, and marketable securities

HAYWARD, California [Business Wire] — November 5, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the third quarter ended September 30, 2026.

“Pulse Biosciences delivered several major milestones since the second quarter, led by completing enrollment in our U.S. pivotal IDE study in just six months, three months ahead of plan,” said Paul LaViolette, CEO and Co Chairman of Pulse Biosciences. “That speed reflects the growing enthusiasm physicians have shown for the nPulse catheter since their very first cases. We also meaningfully strengthened our balance sheet, represented by institutional investor conviction in the opportunities ahead enabled by our technology and our team. With NANOPULSE-AF fully enrolled, and the capital to execute, we are now focused on preparations for launch readiness, additional data readouts, and regulatory submissions. We are also advancing new clinical study initiatives and exciting product development innovations, reflecting the deep application pipeline for our platform technology that gives us the opportunity to bring nsPFA to very large, underserved patient populations.”

Recent Business Highlights

●

Cash, cash equivalents, and marketable securities totaled $189.2 million as of September 30, 2026, compared to $101.6 million as of June 30, 2026. Based on current yields on cash, cash equivalents, and marketable securities at the current balance, provides over $7.5 million in annual interest income.

●

The Company raised $95.8 million in net proceeds through its ATM programs during the third quarter, and more than $150 million since May representing less than 6% dilution.

Endocardial Catheter AF Ablation

●

Completed enrollment in NANOPULSE-AF, the U.S. IDE pivotal study of the nPulse Cardiac Catheter System for the treatment of atrial fibrillation (AF), with 169 evaluable patients at 15 sites with 36 investigators. Enrollment was completed in under six months, three months faster than the timeline originally communicated.

●

Plans to present 12-month follow up data on 100 patients from the EU feasibility study in Q1 2027.

●

Continued to progress toward a CE Mark submission with anticipated CE mark approval in Q4 2027.

●

Plans to submit an IDE application for a persistent AF study in the fourth quarter of 2026, extending the nPulse catheter platform to larger and more complex patient groups.

Surgical AF Ablation and Soft Tissue Ablation

●

Continued to enroll NANOCLAMP-AF, the U.S. IDE pivotal study for concomitant surgical AF ablation, which remains on track to complete enrollment by the end of the first half of 2027. First patient enrolled in the trial has reached one year follow-up.

●

Recorded $0.4 million of third quarter revenue from Vybrance, compared to $0.1 million in the prior year period, while commercial case volume increased from prior quarters and important market development milestones were achieved focusing on existing account development.

●

Completed enrollment of the PRECISE-Benign Thyroid Nodule (PRECISE-BTN) study in September with 100 patients. Preliminary data are being presented at the American Thyroid Association annual meeting, with further data readouts expected after all patients achieve six-month and twelve-month follow-up.

Third Quarter 2026 Financial Results

Total revenue for the three months ended September 30, 2026 was $0.4 million, compared to $0.1 million in the prior year period. The Company remains in a controlled commercial launch of its Vybrance system, directing efforts toward market development and clinical use within a limited customer base. Results continue to be encouraging, we expect this phase of the Vybrance controlled launch to continue into Q4 2027.

Total GAAP costs and expenses, representing cost of product revenue, research and development, and selling, general and administrative expenses, for the three months ended September 30, 2026, were $24.7 million, an increase of $4.2 million compared to $20.5 million in the prior year period. The increase was primarily driven by increased investment in clinical program and employee-related spend. Non-GAAP costs and expenses for the three months ended September 30, 2026, were $19.1 million, an increase of $4.5 million compared to $14.6 million in the prior year period, driven by increased clinical program and employee-related spend.

GAAP net loss for the three months ended September 30, 2026 was ($23.1) million compared to ($19.4) million for the three months ended September 30, 2025. Non-GAAP net loss for the three months ended September 30, 2026, was ($17.5) million compared to ($13.5) million for the three months ended September 30, 2025.

Cash, cash equivalents, and marketable securities totaled $189.2 million as of September 30, 2026, compared to $101.6 million in cash and cash equivalents as of June 30, 2026. The sequential increase of $87.6 million reflects net proceeds raised under the Company’s ATM programs. Cash used in operating activities in the third quarter of 2026 totaled $15.3 million, compared to $13.0 million in the same period of the prior year and $18.7 million in the second quarter of 2026.

The Company raised $95.8 million in net proceeds through its ATM programs during the third quarter, bringing the total since May to more than $150 million, representing under 6% dilution. Approximately $64 million of ATM capacity remains available.

Reconciliations of GAAP to Non-GAAP costs and expenses and net loss have been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

Webcast and Conference Call Information

Pulse Biosciences’ management will host a conference call Thursday, November 5, 2026, beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 9464498. A live and recorded webcast of the event will be available at https://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Non-GAAP Financial Measures

In this press release, in order to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance. Company management uses these measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for financial and operational decision-making. Non-GAAP adjustments include stock-based compensation, depreciation and amortization, and a legal settlement. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to management and investors. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company’s business.

Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company’s non-GAAP financial measures as tools for comparison. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude non-cash expenses for stock-based compensation, depreciation and amortization and legal settlement expenses.

Glossary of Terms

●

Arrhythmia: Any abnormal heart rhythm where the heart beats too fast, too slow, or irregularly due to electrical disturbances.

●

Atrial arrhythmia: Any abnormal heart rhythm originating in the atria, including AF, atrial flutter, and atrial tachycardia.

●

Atrial fibrillation (AF): Irregular, often rapid heartbeat starting in the atria that can cause symptoms and increase stroke risk.

●

Atrial tachycardia (AT): A rapid abnormal heart rhythm caused by electrical activity originating in the atria outside the heart’s normal pacemaker (sinus node).

●

Cavo tricuspid Isthmus (CTI): A region of right atrial tissue between the inferior vena cava and tricuspid valve that forms part of the electrical circuit in typical atrial flutter.

●

Electroanatomic mapping: 3D mapping of heart chambers that combines anatomy and electrical data to guide ablation.

●

Electrophysiology (EP): Cardiology subspecialty focused on the heart’s electrical system and the diagnosis and treatment of arrhythmias.

●

Myocardial Infarction (MI): Death of heart muscle tissue due to prolonged inadequate blood flow and oxygen supply, commonly called a heart attack.

●

Paroxysmal atrial fibrillation: AF episodes that start and stop on their own, typically lasting less than seven days.

●

Persistent Atrial Fibrillation: Continuous AF lasting more than seven days.

●

Pulsed Field Ablation (PFA): Non‑thermal ablation using short, high‑voltage pulses to selectively injure cardiac cells via irreversible electroporation.

●

Posterior Wall Isolation (PWI): Ablation technique that electrically isolates the posterior wall of the left atrium to target electrical activity that may initiate or sustain AT or AF.

●

Premature ventricular contraction (PVC): An early heartbeat originating in the ventricles that interrupts the normal heart rhythm and may feel like a skipped beat.

●

Pulmonary vein isolation (PVI): Ablation technique that electrically isolates the pulmonary veins from the left atrium to prevent AF triggers.

●

Ventricular Tachycardia (VT): A rapid abnormal heart rhythm originating in the ventricles that can impair blood flow and may be life-threatening.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device such as the nPulse Cardiac Catheter System, statements concerning the anticipated timing of enrollment completion and possible outcomes in any of the Company’s clinical trials, statements concerning any of the Company’s regulatory submissions, including CE Mark submissions, FDA submissions, the planned IDE application for persistent AF and the potential regulatory approval of any Company product, Pulse Biosciences’ expectations, whether stated or implied, about whether the Company’s nsPFA technology will become either a disruptive treatment option or a superior option for treating atrial fibrillation or any other medical condition, statements relating to the effectiveness of the Company’s nsPFA technology and nPulse System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company’s expected product development efforts, such as advancement of its nPulse Cardiac Catheter to treat atrial fibrillation, statements concerning market development and market opportunities, customer adoption and future commercialization of any nPulse product, such as the Vybrance Percutaneous Electrode System, statements concerning the Company’s partnership, manufacturing and financing activities, including its expected cash runway and available capacity under its ATM programs, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Contacts:

Investors:

Pulse Biosciences, Inc.

Jon Skinner, CFO

IR@pulsebiosciences.com

Gilmartin Group

Philip Trip Taylor

415.937.5406

philip@gilmartinir.com

PULSE BIOSCIENCES, INC.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)

September 30,

December 31,

2026

2025

ASSETS

Current assets:

Cash and cash equivalents

36,725

80,735

Marketable securities

152,469

—

Accounts receivable

297

274

Inventory

232

136

Prepaid expenses and other current assets

2,485

2,276

Total current assets

192,208

83,421

Property and equipment, net

1,073

1,051

Intangible assets, net

575

Goodwill

2,791

Right-of-use assets

5,059

6,010

Other assets

398

691

Total assets

201,584

94,539

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

3,018

2,777

Accrued liabilities

8,630

3,576

Lease liability, current

1,747

1,570

Total current liabilities

13,395

7,923

Lease liability, less current portion

4,616

5,960

Total liabilities

18,011

13,883

Stockholders’ equity:

Preferred stock, $0.001 par value; authorized – 50,000,000 shares; no shares issued and outstanding

—

Common stock, $0.001 par value; authorized – 500,000,000 shares; issued and outstanding – 73,314,797 shares and 67,839,689 shares as of September 30, 2026 and December 31, 2025, respectively

Additional paid-in capital

713,153

543,869

Accumulated other comprehensive loss

(83

)

—

Accumulated deficit

(529,570

)

(463,281

)

Total stockholders’ equity

183,573

80,656

Total liabilities and stockholders’ equity

201,584

94,539

PULSE BIOSCIENCES, INC.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

Three Months Ended

Nine Months Ended

September 30,

2026

2025

2026

2025

Revenue:

Product revenue

395

1,230

Cost and expenses:

Cost of product revenue

191

279

834

279

Research and development

16,848

11,393

46,414

33,794

Selling, general and administrative

7,648

8,781

22,696

24,699

Total cost and expenses

24,687

20,453

69,944

58,772

Loss from operations

(24,292

)

(20,367

)

(68,714

)

(58,686

)

Other income (expense):

Interest income

1,205

1,001

2,398

3,385

Other income (expense)

(19

)

(47

)

Total other income

1,241

982

2,425

3,338

Net loss

(23,051

)

(19,385

)

(66,289

)

(55,348

)

Net loss per share, basic and diluted

(0.32

)

(0.29

)

(0.95

)

(0.82

)

Weighted average common shares outstanding, basic and diluted

71,929,228

67,385,281

69,722,351

67,263,426

Three Months Ended

Nine Months Ended

September 30,

Stock Based Compensation Expense:

2026

2025

2026

2025

Cost of product revenue

Research and development

2,275

2,232

6,560

7,329

Selling, general and administrative

3,017

3,333

5,545

9,106

Total stock-based compensation expense

5,312

5,617

12,197

16,487

Reconciliation of GAAP to Non-GAAP Financial Measures

The following table presents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures:

(In thousands)

(Unaudited)

Three Months Ended

Nine Months Ended

September 30,

2026

2025

2026

2025

Reconciliation of GAAP to non-GAAP Cost of product revenue:

GAAP Cost of product revenue

191

279

834

279

Stock-based compensation expense

(20

)

(52

)

(92

)

(52

)

Depreciation and amortization

—

)

—

)

Non-GAAP Cost of product revenue

171

224

742

224

Reconciliation of GAAP to non-GAAP Research and development:

GAAP Research and development

16,848

11,393

46,414

33,794

Stock-based compensation expense

(2,275

)

(2,232

)

(6,560

)

(7,329

)

Depreciation and amortization

(48

)

(41

)

(134

)

(131

)

Non-GAAP Research and development

14,525

9,120

39,720

26,334

Reconciliation of GAAP to non-GAAP Selling, general and administrative:

GAAP Selling, general and administrative

7,648

8,781

22,696

24,699

Stock-based compensation expense

(3,017

)

(3,333

)

(5,545

)

(9,106

)

Depreciation and amortization

(213

)

(212

)

(636

)

(678

)

Legal settlement

—

590

Non-GAAP Selling, general and administrative

4,418

5,236

16,515

15,505

Reconciliation of GAAP to non-GAAP Cost and expenses:

GAAP Cost and expenses

24,687

20,453

69,944

58,772

Stock-based compensation expense

(5,312

)

(5,617

)

(12,197

)

(16,487

)

Depreciation and amortization

(261

)

(256

)

(770

)

(812

)

Legal settlement

—

590

Non-GAAP Cost and expenses

19,114

14,580

56,977

42,063

Reconciliation of GAAP to non-GAAP Net loss:

GAAP Net loss

(23,051

)

(19,385

)

(66,289

)

(55,348

)

Stock-based compensation expense

5,312

5,617

12,197

16,487

Depreciation and amortization

261

256

770

812

Legal settlement

—

(590

)

Non-GAAP Net loss

(17,478

)

(13,512

)

(53,322

)

(38,639

)

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Document And Entity Information

Nov. 05, 2026

Document Information [Line Items]

Entity, Registrant Name

Pulse Biosciences, Inc.

Document, Type

8-K

Document, Period End Date

Nov. 05, 2026

Entity, Incorporation, State or Country Code

Entity, File Number

001-37744

Entity, Tax Identification Number

46-5696597

Entity, Address, Address Line One

3957 Point Eden Way

Entity, Address, City or Town

Hayward

Entity, Address, State or Province

Entity, Address, Postal Zip Code

94545

City Area Code

510

Local Phone Number

906-4600

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, $0.001 par value per share

Trading Symbol

PLSE

Security Exchange Name

NASDAQ

Entity, Emerging Growth Company

false

Amendment Flag

false

Entity, Central Index Key

0001625101

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration